Literature DB >> 455579

Vindesine. A short review of preclinical and first clinical data.

R W Dyke, R L Nelson, W P Brade.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 455579     DOI: 10.1007/bf00257185

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  17 in total

Review 1.  Microtubules as drug receptors: pharmacological properties of microtubule protein.

Authors:  L Wilson
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

Review 2.  Neurotoxicity of commonly used antineoplastic agents (first of two parts).

Authors:  H D Weiss; M D Walker; P H Wiernik
Journal:  N Engl J Med       Date:  1974-07-11       Impact factor: 91.245

Review 3.  Vincristine neurotoxicity.

Authors:  S Rosenthal; S Kaufman
Journal:  Ann Intern Med       Date:  1974-06       Impact factor: 25.391

4.  Vincristine neuropathy. Clinical and electrophysiological observations.

Authors:  E B Casey; A M Jellife; P M Le Quesne; Y L Millett
Journal:  Brain       Date:  1973       Impact factor: 13.501

5.  The binding of vinblastine to tubulin and to particulate fractions of mammalian brain.

Authors:  R J Owellen; D W Donigian; C A Hartke; R M Dickerson; M J Kuhar
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

6.  Therapy of advanced squamous carcinoma of the lung: cyclophosphamide vesus "COMB".

Authors:  G P Bodey; S W Lagakos; A C Gutierrez; H E Wilson; O S Selawry
Journal:  Cancer       Date:  1977-03       Impact factor: 6.860

7.  Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro.

Authors:  R H Himes; R N Kersey; I Heller-Bettinger; F E Samson
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

Review 8.  Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

Authors:  R W Dyke; R L Nelson
Journal:  Cancer Treat Rev       Date:  1977-06       Impact factor: 12.111

9.  Phase II clinical trial with vindesine for remission induction in acute leukemia, blastic crisis of chronic myeloid leukemia, lymphosarcoma, and hodgkin's disease: absence of cross-resistance with vincristine.

Authors:  G Mathé; J L Misset; F De Vassal; J Gouveia; M Hayat; D Machover; D Belpomme; J L Pico; L Schwarzenberg; P Ribaud; M Musset; C Jasmin; L De Luca
Journal:  Cancer Treat Rep       Date:  1978-05

10.  Ultrastructural localization of the high molecular weight proteins associated with in vitro-assembled brain microtubules.

Authors:  W L Dentler; S Granett; J L Rosenbaum
Journal:  J Cell Biol       Date:  1975-04       Impact factor: 10.539

View more
  6 in total

Review 1.  A Review on Mechanistic Insight of Plant Derived Anticancer Bioactive Phytocompounds and Their Structure Activity Relationship.

Authors:  Kishor Mazumder; Asma Aktar; Priyanka Roy; Biswajit Biswas; Md Emran Hossain; Kishore Kumar Sarkar; Sitesh Chandra Bachar; Firoj Ahmed; A S M Monjur-Al-Hossain; Koichi Fukase
Journal:  Molecules       Date:  2022-05-09       Impact factor: 4.927

2.  Pharmacokinetics of vindesine bolus and infusion.

Authors:  D V Jackson; V S Sethi; T R Long; H B Muss; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

3.  Vindesine effect in myeloid leukemia.

Authors:  M Baccarani; A Zaccaria; G Corbelli; S Tura
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Experimental in vivo cross-resistance of vinca alkaloid drugs.

Authors:  R Maral; C Bourut; E Chenu; G Mathe
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

5.  Neurological toxicity of vindesine used in combination chemotherapy of 51 human solid tumors.

Authors:  C Focan; R Olivier; S Le Hung; R Bays; J J Claessens; H Debruyne
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Vindesine: phase II evaluation in colon cancer and description of its platelet stimulating activity.

Authors:  R Pazdur; A H Rossof; G Chandra; P D Bonomi; R E Slayton; J Wolter
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.